APLT Relative Valuation
APLT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLT is overvalued; if below, it's undervalued.
Historical Valuation
Applied Therapeutics Inc (APLT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.14. The fair price of Applied Therapeutics Inc (APLT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.21
Fair
-0.47
PE
1Y
3Y
5Y
Trailing
Forward
-0.23
EV/EBITDA
Applied Therapeutics Inc. (APLT) has a current EV/EBITDA of -0.23. The 5-year average EV/EBITDA is -2.35. The thresholds are as follows: Strongly Undervalued below -10.30, Undervalued between -10.30 and -6.32, Fairly Valued between 1.62 and -6.32, Overvalued between 1.62 and 5.60, and Strongly Overvalued above 5.60. The current Forward EV/EBITDA of -0.23 falls within the Historic Trend Line -Fairly Valued range.
-0.26
EV/EBIT
Applied Therapeutics Inc. (APLT) has a current EV/EBIT of -0.26. The 5-year average EV/EBIT is -2.00. The thresholds are as follows: Strongly Undervalued below -7.81, Undervalued between -7.81 and -4.91, Fairly Valued between 0.90 and -4.91, Overvalued between 0.90 and 3.80, and Strongly Overvalued above 3.80. The current Forward EV/EBIT of -0.26 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Applied Therapeutics Inc. (APLT) has a current PS of 0.00. The 5-year average PS is 88.85. The thresholds are as follows: Strongly Undervalued below -414.76, Undervalued between -414.76 and -162.95, Fairly Valued between 340.66 and -162.95, Overvalued between 340.66 and 592.47, and Strongly Overvalued above 592.47. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Applied Therapeutics Inc. (APLT) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.88. The thresholds are as follows: Strongly Undervalued below -9.44, Undervalued between -9.44 and -5.66, Fairly Valued between 1.90 and -5.66, Overvalued between 1.90 and 5.68, and Strongly Overvalued above 5.68. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Applied Therapeutics Inc. (APLT) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.88. The thresholds are as follows: Strongly Undervalued below -10.65, Undervalued between -10.65 and -6.77, Fairly Valued between 1.01 and -6.77, Overvalued between 1.01 and 4.89, and Strongly Overvalued above 4.89. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Applied Therapeutics Inc (APLT) has a current Price-to-Book (P/B) ratio of -54.33. Compared to its 3-year average P/B ratio of -9.97 , the current P/B ratio is approximately 444.79% higher. Relative to its 5-year average P/B ratio of -4.64, the current P/B ratio is about 1071.56% higher. Applied Therapeutics Inc (APLT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -82.24%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -88.51% , the current FCF yield is about -100.00% lower.
-59.15
P/B
Median3y
-9.97
Median5y
-4.64
-284.97
FCF Yield
Median3y
-82.24
Median5y
-88.51
Competitors Valuation Multiple
The average P/S ratio for APLT's competitors is 0.00, providing a benchmark for relative valuation. Applied Therapeutics Inc Corp (APLT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of 719.67%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APLT decreased by 73.15% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 122.00K to 1,000K.
The secondary factor is the Margin Expansion, contributed -96.62%to the performance.
Overall, the performance of APLT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Applied Therapeutics Inc (APLT) currently overvalued or undervalued?
What is Applied Therapeutics Inc (APLT) fair value?
How does APLT's valuation metrics compare to the industry average?
What is the current P/B ratio for Applied Therapeutics Inc (APLT) as of Dec 05 2025?
What is the current FCF Yield for Applied Therapeutics Inc (APLT) as of Dec 05 2025?
What is the current Forward P/E ratio for Applied Therapeutics Inc (APLT) as of Dec 05 2025?